Polyendocrine metabolic ovarian syndrome officially replaced polycystic ovary syndrome in May 2026, shifting clinical focus away from ovarian cysts toward systemic endocrine and metabolic dysfunction.
Shifting the Clinical Lens Beyond Ovarian Cysts
The former diagnosis of polycystic ovary syndrome placed primary emphasis on cysts in the ovaries. However, medical professionals said that cysts are neither universally present nor the defining feature of the condition, which impacts one in eight women globally, totaling more than 170 million individuals, as reported by Yahoo Health.
“The problem is bigger than ovaries,” said Dr. Katelyn Powell, a North Mississippi Health Services family medicine resident. “It affects the hormones, metabolism, energy, weight, among other things. The name change puts the emphasis on the endocrine and metabolic systems.”
The revised terminology—polyendocrine metabolic ovarian syndrome (PMOS)—arose from a global effort spanning over a decade to establish a more accurate title. Professor Helena Teede, an endocrinologist and member of the Endocrine Society, explained the reality behind the former diagnostic terminology.
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” Teede said, as detailed by The Knight News.
The Endocrine Society said that achieving this nomenclature modification required fourteen years of international collaboration among experts and individuals with lived experience. The condition involves multiple systems across the body, and medical practitioners track trends through family history, menstrual history, and blood panels because the overarching condition manifests differently depending on the woman. Symptoms encompass oligomenorrhea, which describes having fewer than nine menstrual cycles a year along with irregular or very light periods, alongside acne, weight changes, fertility challenges, and excessive hair growth in a male-like pattern on areas such as the face, chest, back, or abdomen.
Diagnosis involves evaluating health history and physical exams, potentially supplemented by ultrasounds and blood tests measuring high levels of androgens and other hormones. A diagnosis may lead physicians to recommend regular checks of blood pressure, cholesterol, and triglyceride levels, alongside screenings for depression, anxiety, and obstructive sleep apnea.
Because the condition captures polyendocrine hormonal systems, metabolic functions, and various physical and emotional symptoms, it accounts for approximately 10 percent to 12.5 percent of women worldwide. Furthermore, public health advocates emphasize that diagnostic criteria should account for specific racial and ethnic backgrounds to prevent missed treatment opportunities, noting that hirsutism is more prevalent in South Asian, Middle Eastern, and Hispanic populations, whereas East Asian populations exhibit less hirsutism and body fat.
In response, Teede, who also serves as Director of the Monash Centre for Health Research & Implementation (MCHRI) and led the Lancet paper announcing the transition, said that those objections were “very easy to refute,” as noted by Medical Republic.
Teede emphasized that the former naming convention caused clear, demonstrable harm by missing diverse care needs, adding that the evidence for distinct subtypes remains insufficient to alter clinical guidelines at this stage. Professor Dunaif and Professor Ehrmann also argued that objections were never independently reviewed and that no organization could assess the name or its scientific justification prior to its official announcement.
Researchers Debate Scientific Accuracy of PMOS Subtypes
Despite the official adoption of PMOS, the change has generated debate among medical researchers. According to US doctors, the guidelines failed to consider “genomic analyses, disease subtyping, or the literature on the male phenotype.”
In response, Teede said that the commentary “missed the point” about harms to people with lived experience, adding that the evidence for distinct subtypes is not strong enough to alter clinical guidelines at this stage.
Teede also noted the importance of practitioners “lifting their sights” beyond reproductive health by recognising PMOS as a systems-endocrine disorder and assessing patients for all features, including metabolic, reproductive, skin, and mental health complications, throughout their lifetime.
Systemic Health Risks and Lived Experience
Beyond reproductive symptoms such as irregular periods and fertility challenges, PMOS carries significant metabolic implications. Powell said that affected individuals face elevated risks for Type II diabetes, high blood pressure, cardiology issues, and endometrial cancer.
A review published in the Journal of the Endocrine Society further indicated that women with PMOS may experience a higher likelihood of developing Alzheimer’s disease and dementia, mediated largely by metabolic comorbidities like insulin resistance and obesity, as reported by News-Medical. This review was authored by Ricardo Azziz of the University of Alabama at Birmingham alongside Mina Amiri of Tehran University of Medical Sciences and other colleagues.
Qualitative research published in BMC Women’s Health evaluated how patients conceptualize these challenges, examining 50 women diagnosed via Rotterdam criteria at an Istanbul hospital between October 10 and December 15, 2025, as covered by Bioengineer. Across the analyzed participant responses, journey metaphors characterized overall living with the condition among 46 percent of participants and represented the primary fear for 56 percent of respondents.
“It is a lifelong syndrome,” Powell said. “But with lifestyle changes and medicines to help with symptoms, it can be well managed.”